
Subcutaneous Semaglutide 2.4 mg Triples MASH Resolution Rates in 800-Patient Phase 3 Trial
Once-weekly subcutaneous semaglutide 2.4 mg achieved a near-quadrupling of MASH

Once-weekly subcutaneous semaglutide 2.4 mg achieved a near-quadrupling of MASH

Continued treatment with resmetirom (Rezdiffra), a liver-directed thyroid hormone receptor-

A systematic review and meta-analysis pools published CSF biomarker studies

A prospective study evaluating the impact of six months of

A comparative analysis of routine inflammation markers in rheumatoid arthritis

A Spanish single-centre cross-sectional study in 88 non-obese inflammatory arthritis

The urticaria sessions reinforced an emerging consensus that chronic spontaneous

A preregistered propensity score-matched cohort study across approximately 300,000 matched

A prospective single-centre observational series of omalizumab in paediatric chronic

An assessment of where endotype-directed prescribing now stands following two

A guideline-focused teaching lecture covering classification, diagnostic work-up and treat-to-target

An expert overview of pathomechanism and the emerging therapeutic pipeline,